These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 38772194)

  • 1. Canada's THC unit: Applications for the legal cannabis market.
    Wood S; Gabrys R; Freeman T; Hammond D
    Int J Drug Policy; 2024 Jun; 128():104457. PubMed ID: 38772194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cannabis labelling and consumer understanding of THC levels and serving sizes.
    Leos-Toro C; Fong GT; Meyer SB; Hammond D
    Drug Alcohol Depend; 2020 Mar; 208():107843. PubMed ID: 32044091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Communicating THC levels and 'dose' to consumers: Implications for product labelling and packaging of cannabis products in regulated markets.
    Hammond D
    Int J Drug Policy; 2021 May; 91():102509. PubMed ID: 31351756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Tetrahydrocannabinol Content and Price in Herbal Cannabis Products Offered by Dispensaries in California: A Purview of Consumers/Patients.
    Dobbins M; Rakkar M; Cunnane K; Pennypacker SD; Wagoner KG; Reboussin BA; Romero-Sandoval EA
    Front Public Health; 2022; 10():893009. PubMed ID: 35784239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 'Standard THC units': a proposal to standardize dose across all cannabis products and methods of administration.
    Freeman TP; Lorenzetti V
    Addiction; 2020 Jul; 115(7):1207-1216. PubMed ID: 31606008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Self-reported THC content and associations with perceptions of feeling high among cannabis consumers.
    Lineham J; Wadsworth E; Hammond D
    Drug Alcohol Rev; 2023 Jul; 42(5):1142-1152. PubMed ID: 37062952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploring consumer preferences for cannabis edible products to support public health policy: A discrete choice experiment.
    Donnan J; Johnston K; Coombs M; Najafizada M; Bishop L
    PLoS One; 2024; 19(5):e0292336. PubMed ID: 38753807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Growing pains: An overview of cannabis quality control and quality assurance in Canada.
    Pusiak RJ; Cox C; Harris CS
    Int J Drug Policy; 2021 Jul; 93():103111. PubMed ID: 33478804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cannabis Legalization and Detection of Tetrahydrocannabinol in Injured Drivers.
    Brubacher JR; Chan H; Erdelyi S; Staples JA; Asbridge M; Mann RE
    N Engl J Med; 2022 Jan; 386(2):148-156. PubMed ID: 35020985
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How should policymakers regulate the tetrahydrocannabinol content of cannabis products in a legal market?
    Hall W; Leung J; Carlini BH
    Addiction; 2023 Jun; 118(6):998-1003. PubMed ID: 36662648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Limitations to the Dutch cannabis toleration policy: Assumptions underlying the reclassification of cannabis above 15% THC.
    Van Laar M; Van Der Pol P; Niesink R
    Int J Drug Policy; 2016 Aug; 34():58-64. PubMed ID: 27471078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparative analysis of laws on recreational cannabis edibles between Canada and the United States of America.
    Goundar P; Macaulay T; Szafron M
    Int J Drug Policy; 2021 Aug; 94():103191. PubMed ID: 33756442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Knowledge of Tetrahydrocannabinol and Cannabidiol Levels Among Cannabis Consumers in the United States and Canada.
    Hammond D; Goodman S
    Cannabis Cannabinoid Res; 2022 Jun; 7(3):345-354. PubMed ID: 33998866
    [No Abstract]   [Full Text] [Related]  

  • 14. Threaten, Distract, and Discredit: Cannabis Industry Rhetoric to Defeat Regulation of High-THC Cannabis Products in Washington State.
    Carlini BH; Kellum LB; Garrett SB; Nims LN
    J Stud Alcohol Drugs; 2024 May; 85(3):322-329. PubMed ID: 38270913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patterns of delta 8 THC and cannabis uptake in Nebraska: A cannabis prohibition state.
    Humeniuk R; Habecker P; Cooper-Ohm S; Bevins RA
    Int J Drug Policy; 2024 May; 127():104400. PubMed ID: 38554564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Using Transformer-Based Topic Modeling to Examine Discussions of Delta-8 Tetrahydrocannabinol: Content Analysis.
    Smith BP; Hoots B; DePadilla L; Roehler DR; Holland KM; Bowen DA; Sumner SA
    J Med Internet Res; 2023 Dec; 25():e49469. PubMed ID: 38127427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Variation in cannabis potency and prices in a newly legal market: evidence from 30 million cannabis sales in Washington state.
    Smart R; Caulkins JP; Kilmer B; Davenport S; Midgette G
    Addiction; 2017 Dec; 112(12):2167-2177. PubMed ID: 28556310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessing New Zealand's Cannabis Legalization and Control Bill: prospects and challenges.
    Wilkins C; Rychert M
    Addiction; 2021 Feb; 116(2):222-230. PubMed ID: 32621400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Public interest in ∆
    Leas EC; Nobles AL; Shi Y; Hendrickson E
    Int J Drug Policy; 2022 Mar; 101():103557. PubMed ID: 34952279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. From Toques to Tokes: Two challenges facing nationwide legalization of cannabis in Canada.
    Bear D
    Int J Drug Policy; 2017 Apr; 42():97-101. PubMed ID: 28377052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.